DNAprint inks psychiatric drug research pact with Massachusetts College of Pharmacy, Health Sciences

By Ted A. Knutson

Washington, Feb. 7 - DNAprint genomics Inc. said Tuesday it has entered into a research sponsorship agreement with the Massachusetts College of Pharmacy and Health Sciences for sponsored research in connection with the synthesis and testing of certain compounds as possible medicines for drug abuse, attention deficit hyperactivity disorder and depression.

The research will be conducted under the supervision of Dr. Mark Froimowitz. The company had previously licensed exclusive rights to the compounds from Froimowitz on Oct. 19 under an exclusive licensing agreement.

The sponsored research payments total $300,000 over one year.

Based in Sarasota, Fla., DNAprint is a genomic research company.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.